^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PRRC2C (Proline Rich Coiled-Coil 2C)

    i
    Other names: PRRC2C, Proline Rich Coiled-Coil 2C, XTP2, KIAA1096, BAT2D1, BAT2L2, Proline-Rich And Coiled-Coil-Containing Protein 2C, HLA-B-Associated Transcript 2-Like 2, HBV X-Transactivated Gene 2 Protein, BAT2 Domain-Containing Protein 1, HBV XAg-Transactivated Protein 2, BAT2 Domain Containing 1, Protein PRRC2C, HLA-B Associated Transcript 2-Like, HBxAg Transactivated Protein 2, Proline-Rich Coiled-Coil 2C, Protein BAT2-Like 2, BAT2-Iso
    6ms
    Programmatically Efficient Separation of Immune Infiltrate and Tumor Gene Expression Overlap Potentials in a Big Data Setting: FASLG Gene Expression-related Survival Distinctions. (PubMed, Cancer Genomics Proteomics)
    This study indicates that FASLG CN increases could represent a mechanism of tumor escape from TILs and a prognostic indicator; and tumor FASLG may be a suitable drug target for reducing tumor evasion of T-cells.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FASLG (Fas ligand) • PRRC2C (Proline Rich Coiled-Coil 2C)
    12ms
    Potential Common Molecular Mechanisms Between Periodontitis and Prostate Cancer: A Network Analysis of Differentially Expressed miRNAs. (PubMed, In Vivo)
    Our study suggests candidate molecular mechanisms linking periodontitis to prostate cancer, highlighting potential compounds targeting both diseases. These findings provide a foundation for guiding future basic and clinical research.
    Journal
    |
    TP53 (Tumor protein P53) • DNMT1 (DNA methyltransferase 1) • CREB1 (CAMP Responsive Element Binding Protein 1) • PRRC2C (Proline Rich Coiled-Coil 2C) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • MAT2A (Methionine Adenosyltransferase 2A) • MIR148A (MicroRNA 148a) • MIR148B (MicroRNA 148b) • MIR623 (MicroRNA 623)
    |
    gemcitabine • arsenic trioxide
    2years
    Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases (ASH 2023)
    ST2 and EZB genetic groups stand as the most frequent genetic subtypes of DLBCL NOS. While ST2 is found in either GCB and non-GCB subtypes, EZB is found preferentially in cases with the GCB phenotype, including GCB type DLBCL and HGBCL/DLBCL DH. In comparison with already published series we found a relatively higher prevalence of the ST2 genetic subtype among DLBCL NOS.
    Clinical • Tumor mutational burden • IO biomarker • Whole exome sequencing
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • EP300 (E1A binding protein p300) • CLTC (Clathrin Heavy Chain) • DOCK8 (Dedicator Of Cytokinesis 8) • PRKCB (Protein Kinase C Beta) • PRRC2C (Proline Rich Coiled-Coil 2C) • PABPC1 (Poly(A) Binding Protein Cytoplasmic 1)
    |
    TP53 mutation • TET2 mutation • MYC expression
    over2years
    Safety and efficacy of atezolizumab in Chinese patients with previously treated locally advanced or metastatic non-small cell lung cancer: An open-label, single-arm, multicenter study. (PubMed, Lung Cancer)
    No new safety concerns were raised, and clinically meaningful benefits of atezolizumab monotherapy were shown. The results of the biomarker analyses may guide future therapeutic strategies.
    Clinical • Journal • PD(L)-1 Biomarker • Metastases
    |
    CD8 (cluster of differentiation 8) • PRRC2C (Proline Rich Coiled-Coil 2C) • ZMYND8 (Zinc Finger MYND-Type Containing 8)
    |
    Tecentriq (atezolizumab)